However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as a chemist with Erhart’s training as a confectioner. It was a success ...

Some blame Pfizer. The firm is struggling to replace ... the device is rather clunky—about the size of a flashlight, made larger when expanded to the ready position (see photo).

With a market capitalization of more than $143 billion today, Pfizer (NYSE: PFE) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold ...

Pfizer's stock has plummeted due to declining ... years coupled with the relatively expensive acquisition of Seagen (made in order to compensate for these losses) or with the discontinuation ...

The deal with Pfizer and the approval of prGCD “should open the floodgates, in my opinion,” he says. “It is by far the most significant development in the plant-made pharmaceuticals arena ...

I think the current valuations could make Pfizer very noticeable in the volatile and overvalued market in 2025 if the S&P 500 earnings growth cannot keep up pace with the expectation to justify ...

Today, a brief rundown of news involving Pfizer, AbbVie and Royalty Pharma, as well as updates from Biogen and Alkeus Pharmaceuticals that you may have missed. Barinthus Biotherapeutics on Friday said ...

Based on the last payment, the company wasn't making enough to cover what it was ... Over the past five years, it looks as though Pfizer's EPS has declined at around 23% a year.

Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.